BACKGROUND The central role of inflammatory progression in the development of Coronavirus disease 2019 (COVID-19), especially in severe cases, is indisputable. However, the role of some novel inflammatory biomarkers in the prognosis of COVID-19 remains controversial. OBJECTIVE To assess the effect of some novel inflammatory biomarkers in the occurrence and prognosis of COVID-19. METHODS We systematically retrieved the studies related to COVID-19 and the inflammatory biomarkers of interest. The data of each biomarker in different groups were extracted, then were categorized and pooled. The standardized mean difference was chosen as an effect size measure to compare the difference between groups. RESULTS A total of 90 studies with 12,059 participants were included in this study. We found higher levels of endocan, PTX3, suPAR, sRAGE, galectin-3, and monocyte distribution width (MDW) in the COVID-19 positive groups compared to the COVID-19 negative groups. No significant differences for suPAR and galectin-3 were detected between the severe group and mild/moderate group of COVID-19. In addition, the deaths usually had higher levels of PTX3, sCD14-ST, suPAR, and MDW at admission compared to the survivors. Furthermore, patients with higher levels of endocan, galectin-3, sCD14-ST, suPAR, and MDW usually developed poorer comprehensive clinical prognoses. CONCLUSIONS In summary, this meta-analysis provides the most up-to-date and comprehensive evidence for the role of the mentioned novel inflammatory biomarkers in the prognosis of COVID-19, especially in evaluating death and other poor prognoses, with most biomarkers showing a better discriminatory ability.

中文翻译：

---

COVID-19 预后中的新型炎症生物标志物。

背景 炎症进展在 2019 年冠状病毒病（COVID-19）的发展中，尤其是在严重病例中，发挥着核心作用，这是无可争议的。然而，一些新型炎症生物标志物在 COVID-19 预后中的作用仍存在争议。目的 评估一些新型炎症生物标志物对 COVID-19 发生和预后的影响。方法 我们系统地检索了与 COVID-19 和感兴趣的炎症生物标志物相关的研究。提取不同组中每个生物标志物的数据，然后进行分类和汇总。选择标准化平均差作为效应大小测量来比较组间差异。结果 本研究共纳入 90 项研究，共有 12,059 名参与者。我们发现，与 COVID-19 阴性组相比，COVID-19 阳性组的 Endocan、PTX3、suPAR、sRAGE、galectin-3 和单核细胞分布宽度 (MDW) 水平较高。在 COVID-19 重症组和轻/中度组之间，suPAR 和半乳糖凝集素 3 没有检测到显着差异。此外，与幸存者相比，死亡患者入院时的 PTX3、sCD14-ST、suPAR 和 MDW 水平通常较高。此外，endocan、galectin-3、sCD14-ST、suPAR 和 MDW 水平较高的患者通常综合临床预后较差。结论 总之，这项荟萃分析为上述新型炎症生物标志物在 COVID-19 预后中的作用提供了最新、最全面的证据，特别是在评估死亡和其他不良预后方面，大多数生物标志物显示出更好的辨别能力。